Streetbeat News

QNRX

Quoin Pharmaceuticals, Ltd.

Industry

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Open

0.29

Mkt cap

2.5M

Volume

329K

High

0.30

P/E Ratio

-0.16

52-wk high

1.57

Low

0.29

Div yield

N/A

52-wk low

0.27

Several health care stocks experienced significant price movements during Friday's intraday session. Notable gainers included Catheter Precision (AMEX:VTAK) with a 142.8% increase, and Tevogen Bio Holdings (NASDAQ:TVGN) with a 49.28% rise. On the losing side, NKGen Biotech (NASDAQ:NKGN) fell by 31.9%, and Orgenesis (NASDAQ:ORGS) declined by 28.05%.

Portfolio Pulse from Benzinga Insights

October 18, 2024 | 4:31 pm

Quoin Pharmaceuticals shares have been halted after a significant increase of 81.82%.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:33 pm

On Thursday, several health care stocks experienced significant intraday movements. Notable gainers included Tevogen Bio Holdings, Molecular Templates, and Kazia Therapeutics, while Biodexa Pharmaceuticals and 180 Life Sciences were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 4:31 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Molecular Templates (MTEM) saw a 96.6% increase, while Elevance Health (ELV) dropped by 12.47% following its Q3 earnings report. Other notable gainers include Klotho Neurosciences (KLTO) and Healthcare Triangle (HCTI), while Biodexa Pharmaceuticals (BDRX) and 180 Life Sciences (ATNF) were among the losers.

Portfolio Pulse from Benzinga Insights

October 17, 2024 | 12:10 pm

TSMC shares surged 8.1% in pre-market trading due to better-than-expected Q3 results, with revenue up 39% YoY. Other stocks like Staffing 360 Solutions and Gevo also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

October 17, 2024 | 9:39 am

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

Quoin Pharmaceuticals shares have been halted due to a significant upside movement, with the stock price increasing by 157.94%.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:50 pm

Oracle shares surged by 8.8% in pre-market trading after reporting better-than-expected earnings and sales for Q1. Additionally, Oracle and Amazon's AWS launched Oracle Database@AWS, enhancing Oracle's cloud offerings. Other stocks like Silexion Therapeutics and Quoin Pharmaceuticals also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 10, 2024 | 10:41 am

Quoin Pharmaceuticals' CEO and COO have made significant insider purchases of the company's ADSs, indicating strong confidence in the company's growth and direction. This move suggests a positive outlook for Quoin's future as it focuses on treatments for rare and orphan diseases.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 12:40 pm

Quoin Pharmaceuticals reported having approximately $12.6 million in cash, cash equivalents, and marketable securities as of June 30, 2024. This funding is expected to support the company's operations into late 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:33 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.